To learn more about partnering with Chimerix or to initiate a conversation, please contact our Business Development group:
In 2011, Chimerix initiated a partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop brincidofovir (CMX001) as a medical countermeasure to treat smallpox outbreaks due to a bioterror event or accidental release. Brincidofovir has received Fast Track designation from the FDA for smallpox, adenovirus and cytomegalovirus.
CMX157 (Tenofovir Exalidex TXL™), which was licensed to ContraVir Pharmaceuticals, is a novel lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate. TXL is active against hepatitis B virus (HBV) and more than 200-fold more potent in vitro
versus tenofovir against all major HIV subtypes resistant to current therapies. TXL’s novel structure results in decreased circulating levels of tenofovir, lowering systemic exposure and thereby reducing the potential for renal side effects. ContraVir intends to develop TXL as a potential treatment for HBV and HIV. TXL has demonstrated a favorable safety, tolerability and drug distribution profile in a Phase 1 clinical trial in healthy volunteers and is currently being studied in Phase 2 clinical trials.
To learn more about partnering with Chimerix or to initiate a conversation, please contact our Business Development group: firstname.lastname@example.org
Commitment to Those We Serve
At Chimerix, we believe it is critical that scientists, medical professionals, and researchers work together on disease prevention, diagnosis and management. That’s why we offer support, resources and funding.
Our funding focus areas are:
- Charitable contributions
- Research grants
- Third-party educational grants
- Third-party scientific grants
Chimerix provides charitable contributions, including both direct funding and no-charge product, to US 501(c)(3) tax-exempt charitable organizations and to similar organizations worldwide to assist in achieving their charitable missions.
From time-to-time, Chimerix will provide grants to third parties to allow these entities to conduct self-instituted, bona fide medical research aimed at enhancing general scientific knowledge, professional skills and disease awareness. Such research may be of legitimate interest to Chimerix and therefore may be supported through a research grant. A consulting or service agreement is not required in this context, because the researcher is not performing services on Chimerix’s behalf. Rather, the research grant is set forth in a written agreement signed by the grant recipient and Chimerix.
Third-Party Educational Grants.
Chimerix provides funds to sponsor third-party educational programs where certain conditions are met. These programs are conducted by independent, accredited continuing medical education (“CME”) providers and are designed to assist physicians and other professionals in obtaining information that can contribute to the improvement of patient care. Chimerix’s support of CME programs is not intended to promote a particular treatment.
Third-Party Scientific Grants.
Chimerix provides funds to sponsor third-party scientific conferences and seminars where certain conditions are met. These activities are conducted by independent providers and are designed to assist physicians and other professionals in obtaining information that can contribute to the improvement of patient care. Chimerix’s support is not intended to promote a particular treatment.
Apply for funding by e-mailing: email@example.com